Abstract CT104: Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001

Background: Preliminary KEYNOTE-001 data showed that the PD-1 inhibitor pembro has manageable safety and antitumor activity in previously treated and treatment-naive advanced non-small cell lung cancer (NSCLC). In a training set of 182 pts, 129 of whom had measurable disease and tumor evaluable by a...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2015-08, Vol.75 (15_Supplement), p.CT104-CT104
Main Authors: Garon, Edward B., Rizvi, Naiyer, Hui, Rina, Leighl, Natasha B., Balmanoukian, Ani S., Eder, Joseph P., Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew A., Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Zhang, Jin, Rangwala, Reshma A., Lubiniecki, Gregory M., Roach, Charlotte M., Emancipator, Kenneth, Gandhi, Leena
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Preliminary KEYNOTE-001 data showed that the PD-1 inhibitor pembro has manageable safety and antitumor activity in previously treated and treatment-naive advanced non-small cell lung cancer (NSCLC). In a training set of 182 pts, 129 of whom had measurable disease and tumor evaluable by an IHC clinical trial assay (CTA) for PD-L1 expression, ORR was higher in pts with membranous PD-L1 expression in ≥50% of tumor cells (proportion score [PS] ≥50%) vs PS
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2015-CT104